Hanmi creates lineup with Amosartan family, challenging annul KRW 100 million sales
Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) acquired approvals for 2 products of 2-substance combination drug containing the substance of Amosartan, the top sales product. Hanmi is planning to continue the Amosartan wave with 3 products of the ‘Amosartan family’ in the antihypertensive market.
...Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
